The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1249-1256

  Gahr, Susanne ^a   Peter, Gisela ^a   Wissniowski, Thadäus Till ^a   Hahn, Eckhart G ^a   Herold, Christoph ^a   Ocker, Matthias ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

CDK inhibitor; CYC 202; Hepatocellular carcinoma; Histone deacetylase inhibitor; MS 275

Indexed keywords

BROXURIDINE; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE; CYTOKERATIN 18; DNA; HISTONE DEACETYLASE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; ROSCOVITINE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; N (2 AMINOPHENYL) 4 (N (PYRIDIN 3 YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE; N-(2-AMINOPHENYL)-4-(N-(PYRIDIN-3-YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE; PURINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA SYNTHESIS; DRUG POTENTIATION; ENZYME ASSAY; ENZYME INHIBITION; FIBROBLAST; FLOW CYTOMETRY; FLUOROMETRY; FRAGMENTATION REACTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; PREPUCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; WESTERN BLOTTING; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; PURINES; PYRIDINES;

EID: 58149359340     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000137     Document Type: Article

References (41)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Yu AS and Keeffe EB: Management of hepatocellular carcinoma. Rev Gastroenterol Disord 3: 8-24, 2003.
3. Colombo M: Treatment of hepatocellular carcinoma. J Viral Hepat 4 (Suppl 1): 125-130, 1997.
4. Herold C, Reck T, Fischler P, et al: Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver 22: 23-28, 2002.
5. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
6. Schneider-Stock R and Ocker M: Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 10: 557-561, 2007.
7. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
8. Bhalla KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971-3993, 2005.
9. Ocker M and Schneider-Stock R: Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374, 2007.
10. Suzuki T, Ando T, Tsuchiya K, et al: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42: 3001-3003, 1999.
11. Kato Y, Yoshimura K, Shin T, et al: Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 13: 4538-4546, 2007.
12. Qian DZ, Wei YF, Wang X, Kato Y, Cheng L and Pili R: Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 67: 1182-1193, 2007.
13. Gojo I, Jiemjit A, Trepel JB, et al: Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109: 2781-2790, 2007.
14. Saito A, Yamashita T, Mariko Y, et al: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96: 4592-4597, 1999.
15. Vaziri C, Stice L and Faller DV: Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ 9: 465-474, 1998.
16. Coley HM, Shotton CF and Thomas H: Seliciclib (CYC202; rroscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines. Anticancer Res 27: 273-278, 2007.
17. Whittaker SR, Te Poele RH, Chan F, et al: The cyclindependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 6: 3114-3131, 2007.
18. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR and Ibraghimov-Beskrovnaya O: Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444: 949-952, 2006.
19. Atanasova GN, Isaeva AR, Zhelev N, Poumay Y and Mitev VI: Effects of the CDK-inhibitor CYC202 on p38 MAPK, ERK1/2 and c-Myc activities in papillomavirus type 16 E6- and E7- transformed human keratinocytes. Oncol Rep 18: 999-1005, 2007.
20. Dey A, Wong ET, Cheok CF, Tergaonkar V and Lane DP: R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 15: 263-273, 2008.
21. Benson C, White J, De Bono J, et al: A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96: 29-37, 2007.
22. Herold C, Ganslmayer M, Ocker M, et al: The histonedeacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36: 233-240, 2002.
23. Zopf S, Neureiter D, Bouralexis S, et al: Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int J Oncol 31: 1391-1402, 2007.
24. Ocker M, Alajati A, Ganslmayer M, et al: The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131: 385-394, 2005.
25. Hu E, Dul E, Sung CM, et al: Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307: 720-728, 2003.
26. Richon VM, Sandhoff TW, Rifkind RA and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
27. Baradari V, Hopfner M, Huether A, Schuppan D and Scherubl H: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 13: 4458-4466, 2007.
28. Kang KH, Kim WH and Choi KH: p21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp Cell Res 253: 403-412, 1999.
29. Emanuele S, Lauricella M, Carlisi D, et al: SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor bortezomib. Apoptosis 12: 1327-1338, 2007.
30. Kim HR, Kim EJ, Yang SH, et al: Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway? Exp Mol Med 38: 616-624, 2006.
31. Reddy RM, Yeow WS, Chua A, et al: Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondriamediated caspase activation cascade. Apoptosis 12: 55-71, 2007.
32. Wang S, Yan-Neale Y, Cai R, Alimov I and Cohen D: Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 5: 1662-1668, 2006.
33. Gao S, Mobley A, Miller C, Boklan J and Chandra J: Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk Res 32: 771-780, 2008.
34. Chen CS, Wang YC, Yang HC, et al: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67: 5318-5327, 2007.
35. Rosato RR, Almenara JA and Grant S: The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63: 3637-3645, 2003.
36. Rosato RR, Almenara JA, Maggio SC, et al: Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. Mol Cancer Ther 4: 1772-1785, 2005.
37. Cheok CF, Dey A and Lane DP: Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res 5: 1133-1145, 2007.
38. Wesierska-Gadek J and Schmid G: Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein. Expert Opin Investig Drugs 15: 23-38, 2006.
39. Fulda S: Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 8: 132-140, 2008.
40. Morotti A, Cilloni D, Messa F, et al: Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 106: 1188-1196, 2006.
41. Fujikawa K, Shiraki K, Sugimoto K, et al: Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular carcinoma. Anticancer Res 20: 1927-1932, 2000.